Clinical Trial Update: Open Label Safety/Efficacy Study of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Gout Patients [Phase 2]

View source ↗

Summary

Open-label Phase 2 safety and efficacy study of combining arhalofenate with febuxostat for hyperuricemia and gout has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gout
• Hyperuricemia

Drugs mentioned

• Arhalofenate (arhalofenate)
• Febuxostat (Uloric) (febuxostat)

Snippet

Sponsor: Gilead Sciences | Conditions: Hyperuricemia, Gout | Phase 2 | Status: COMPLETED